ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
SOTIO Announces First Patient Dosed in Part B of Phase 1/1b Study with SO-C101 in Combination with Pembrolizumab in Patients with Solid Tumors
July 14, 2020SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that the first patient has been dosed in Part B of the ongoing Phase 1/1b study of IL-15 superagonist, SO-C101, for the treatment of patients with advanced/metastatic soli -
SOTIO Initiates First-In-Human Clinical Trial with IL-15 Superagonist SO-C101
July 12, 2019SOTIO and Cytune Pharma, members of the PPF Group, announce today the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15.
Pharma Sources Insight January 2025
